Sign in
WithdrawnPhase 2

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

Key facts

Who runs it
Uwe Platzbecker
Trial code
Status
Withdrawn
Phase
Phase 2
Started
31 Mar 2024
Expected to end
30 Aug 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Magrolimab
  • 7+3
  • CPX-351
Record updated
12 February 2024
Why it stopped
Trial was stopped prematurely due to safety reasons

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 36 criteriaShow less

Who can take part

  • AML or MDS-IB2 according to WHO 2022 criteria
  • For both MDS and AML: "Intermediate" or "adverse risk" genetic changes according to ELN 2022 category
  • Eligible for and intention to undergo intensive chemotherapy (IC) (CPX-351 or "7+3") followed by allogeneic HSCT, as judged by the investigator

Who cannot take part

  • Patients intended to receive gemtuzumab-ozogamicin during intensive chemotherapy
  • Patients who are not eligible for standard intensive chemotherapy as assessed by the treating physician
  • Previous anthracycline-containing chemotherapy (Exception: cumulative dose for 1 cycle of planned induction therapy (CPX-351 or "7+3") not reached)
  • Any prior treatment for AML or MDS (except for hydroxyurea or treatment for low-risk MDS e.g. growth factors) or prior treatment with CD47 or SIRPα-targeting agents, including magrolimab
  • Known severe cardiopulmonary disease (e.g., unstable angina, congestive heart failure with an EF ≤50%, myocardial infarction within 6 months prior to screening, symptomatic cardiomyopathy, clinically significant arrhythmia17, clinically significant pulmonary hypertension requiring pharmacologic therapy)
  • Major surgery within 14 days of registration or a scheduled surgery during study period, depending on investigator decision
  • Female patients of childbearing potential, who are not using or not willing to use one highly effective method and one additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 6 months after the last dose of study drug. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
  • Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s)
  • Male patients, who do not agree to use an adequate method of contraception, starting with the first dose of study therapy during the entire study treatment period and through 3 months after the last dose of study drug. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
  • Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s)
  • Simultaneous participation in another interventional clinical trial or participation in any clinical trial involving administration of an investigational medicinal product within 30 days prior to MAGROLIC trial registration
  • Medical conditions other than MDS-IB-2 or AML with an estimated life expectancy below 3 months
  • Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Known active Human Immunodeficiency Virus infection (HIV 1/2 antibodies) with detectable viral load
  • Known active Hepatitis B (i.e., HBsAg reactive) or Hepatitis C (i.e., HCV RNA [qualitative] is detected)
  • Diagnosis or treatment for another malignancy within 1 year before registration and currently not in complete remission
  • Any evidence of residual disease of another malignancy
  • Patients with uncontrolled coagulopathy or bleeding disorder
  • Inadequate organ function as defined as any criterion in the list below:; Congestive heart failure or documented cardiomyopathy with an EF ≤50%; Documented pulmonary disease with DLCO ≤65% or FEV1 ≤65%, or dyspnea at rest or requiring oxygen, or any pleural neoplasm or uncontrolled lung neoplasm; On dialysis and age older than 60 years or uncontrolled renal carcinoma; Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) > 5× upper limit of normal (ULN) or liver cirrhosis Child B or C or any biliary tree carcinoma or uncontrolled liver carcinoma or acute viral hepatitis; Bilirubin > 1.5× ULN, or 3.0× ULN and primarily unconjugated if patient has a documented history of Gilbert's syndrome or genetic equivalent; Serum creatinine > 1.5× ULN or calculated glomerular filtration rate (GFR) < 40 mL/min/1.73 m²
  • Known prolonged rate-corrected QT interval ≥ 500 msec, calculated according to Fridericia's formula
  • History or current evidence of any condition, therapy, or laboratory abnormality that might the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
  • Current or planned pregnancy or nursing women (negative urine or serum pregnancy test within 3 days prior to receiving study treatment is needed. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test must be performed.)
  • Age under 18 years at registration
  • Patients harboring a FLT3mut, regardless of FLT3-ITD or FLT3-TKD mutation status and intended to receive midostaurin during induction and consolidation
  • Patient does not accept bone marrow sampling during screening, during and after the treatment
  • Patient does not accept several blood samplings during screening, treatment and after the treatment
  • ECOG performance status of ≥ 3
  • Relapsed or primary refractory AML
  • Acute promyelocytic leukemia
  • Uncontrolled high blood pressure (i.e., systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg)18
  • Known uncontrolled central nervous system (CNS) involvement of MDS-IB-2 or AML (assessment by lumbar puncture is not mandatory for screening)
  • Subject is unable to understand the nature, scope, significance and consequences of this clinical trial or has no legal capacity

About the trial

What the trial wants to find out

Use of magrolimab in combination with standard intensive chemotherapy ("7+3" or CPX-351) in newly diagnosed "ELN 2022 intermediate or adverse-risk" AML or high risk MDS patients, who intend to undergo allogeneic stem cell transplantation

The 2 groups in the trial

  • Magrolimab + intensive chemotherapy (7+3)Treatment being tested

    Patients will receive magrolimab in combination with "7+3"

    Treatment: Magrolimab and 7+3

  • Magrolimab + intensive chemotherapy (CPX-351)Treatment being tested

    Patients will receive magrolimab in combination with CPX-351

    Treatment: Magrolimab and CPX-351

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed "ELN 2022 Intermediate or Adverse-risk" AML or High Risk MDS Patients Intended to Undergo Allogeneic Stem Cell Transplantation, a Phase 2, Single-arm, Open-Label Study
Record updated
12 February 2024